短效避孕藥市場規模、佔有率和成長分析：按產品類型、荷爾蒙類型、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球短效避孕藥市場價值為 2,300 萬美元，預計到 2033 年將從 2025 年的 2,374 萬美元成長到 3,054 萬美元，預測期（2026-2033 年）的複合年成長率為 3.2%。

受數位醫療平台的興起推動，全球短效避孕藥市場正經歷顯著成長。這些平台簡化了處方流程，擴大了用藥管道。遠端醫療使女性，尤其是居住在偏遠地區的女性，能夠透過行動應用程式獲取口服避孕藥，從而最大限度地縮短從諮詢到產品交付的等待時間。這一轉變促使避孕藥的使用量增加，相關研究也證實了這一點，這些研究表明，與線上藥局合作後，避孕藥的普及率顯著提高。為了因應不斷成長的需求，生產商正在其產品線中添加適合藥房分銷的配方，並致力於在新興市場獲得監管部門的批准。因此，新參與企業正在加強其在東南亞等地區的業務，預計在這些地區，財政支持和社區參與舉措將進一步推動銷售成長。

全球短效避孕藥市場成長要素

全球短效避孕市場正經歷顯著成長，這主要得益於消費者對這類方法優勢的認知不斷提高，尤其是與長效避孕方法相比，其柔軟性和易於停用等優點。隨著越來越多的人尋求暫時性的避孕措施，對易於開始和停止使用的產品的需求也日益成長。為此，醫療保健專業人員積極回應患者需求，提案符合不斷變化的生活方式的便捷避孕方案，從而提高了處方率和非處方藥的供應量。這有助於消費者做出明智的選擇，在全球不同人群中形成強勁的成長勢頭，並推動市場擴張。

全球短效避孕藥市場面臨的限制因素

全球短效避孕藥市場面臨許多限制因素，主要源自於監管機構對這類產品中荷爾蒙成分的嚴格監管要求。這些機構要求在產品上市前提供全面的安全數據，這不僅延長了核准流程，還可能導致產品配方需要進行調整以符合不斷變化的標準。因此，企業的產品平臺常常因此受阻，只好將資源投入合規性工作中，而非進行創新。日益沉重的監管負擔不僅阻礙了新產品的上市，也抑制了市場成長，並為投資者和研發人員帶來了相當大的不確定性。

全球短效避孕藥市場趨勢

全球短效避孕藥市場正經歷一場重大變革，而數位化管道的整合正是推動這項變革的動力。電子商務平台和遠端醫療服務的興起正在革新避孕藥的行銷和分銷模式，使品牌能夠更直接、更有效地觸及消費者。透過專注於精準的社群媒體宣傳活動和線上諮詢，企業正在滿足消費者日益成長的便利性和隱私需求，並透過直接面對消費者的訂閱模式培養客戶忠誠度。這種數位化不僅降低了對傳統藥局通路的依賴，還使製造商能夠利用分析數據快速適應不斷變化的消費者偏好，從而獲得競爭優勢。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球短效避孕藥市場規模：依產品類型分類

• 口服避孕藥
• 注射式避孕藥
• 陰道環
• 經皮貼劑
• 其他短效避孕藥

全球短效避孕藥市場規模：依荷爾蒙類型分類

• 荷爾蒙避孕藥
• 僅含黃體素的避孕藥

全球短效避孕藥市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 網路藥房
• 計劃生育診所

全球短效避孕藥市場規模：依最終用戶分類。

• 醫院
• 診所
• 居家照護

全球短效避孕藥市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Bayer AG
• Pfizer Inc.
• Organon & Co.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan NV
• Lupin Limited
• Sun Pharmaceutical Industries Limited
• Cipla Limited
• Viatris Inc.
• Amneal Pharmaceuticals, Inc.
• Mayne Pharma Group Limited
• Exeltis Healthcare SL
• Laboratorios Leon Farma, SA
• HRA Pharma SAS
• Gedeon Richter Plc.
• Shanghai Dahua Pharmaceutical Co., Ltd.
• Janssen Pharmaceuticals, Inc.
• Afaxys Pharma, LLC
• Perrigo Company plc

結論與建議

Global Short Acting Contraceptives Market size was valued at USD 23.0 Million in 2024 and is poised to grow from USD 23.74 Million in 2025 to USD 30.54 Million by 2033, growing at a CAGR of 3.2% during the forecast period (2026-2033).

The global market for short-acting contraceptives is experiencing significant growth, driven by the rise of digital health platforms that simplify the prescription process and expand accessibility. Telemedicine allows women, particularly in remote areas, to access oral contraceptives via mobile applications, thereby minimizing delays between consultation and product delivery. This shift has led to increased contraceptive usage, as evidenced by notable studies indicating substantial uptake boosts following partnerships with e-pharmacies. In response to this heightened demand, manufacturers are broadening their product offerings to include pharmacy-friendly formulations and are focusing on securing regulatory approvals in emerging markets. Consequently, new market entrants are establishing their presence in regions like Southeast Asia, where financial support and community engagement initiatives are projected to further enhance sales growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Short Acting Contraceptives market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Short Acting Contraceptives Market Segments Analysis

Global short acting contraceptives market is segmented by product type, hormone type, distribution channel, end user and region. Based on product type, the market is segmented into Oral Contraceptive Pills, Injectable Contraceptives, Vaginal Rings, Transdermal Patches and Other Short-Acting Contraceptives. Based on hormone type, the market is segmented into Combined Hormonal Contraceptives and Progestin-Only Contraceptives. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Family Planning Clinics. Based on end user, the market is segmented into Hospitals, Clinics and Homecare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Short Acting Contraceptives Market

The Global Short Acting Contraceptives market is experiencing significant growth driven by a rise in consumer awareness regarding the advantages of these methods, particularly their flexibility and quick reversibility compared to long-term options. As individuals increasingly seek temporary pregnancy prevention, they gravitate towards products that offer the ability to initiate or discontinue use with ease. In response, healthcare providers are actively addressing patient needs by suggesting convenient contraceptive solutions that cater to evolving lifestyles, thereby boosting both prescription rates and over-the-counter availability. This empowerment of informed consumer choice is generating strong momentum across various demographic groups worldwide, enhancing the market's expansion.

Restraints in the Global Short Acting Contraceptives Market

The Global Short Acting Contraceptives market faces significant restraints due to the rigorous evaluation procedures imposed by regulatory agencies concerning the hormonal components in these products. These agencies demand comprehensive safety data prior to allowing market entry, which extends approval times and may necessitate alterations in product formulations to comply with changing standards. As a result, companies often encounter delays in their product pipelines and find themselves diverting resources to focus on compliance rather than pursuing innovation. This increased regulatory burden not only hampers the launch of new offerings but also restricts market growth and generates considerable uncertainty for both investors and developers.

Market Trends of the Global Short Acting Contraceptives Market

The Global Short Acting Contraceptives market is experiencing a significant transformation driven by the integration of digital channels. The emergence of e-commerce platforms and telehealth services is revolutionizing the marketing and distribution of contraceptives, enabling brands to reach consumers more directly and effectively. With a focus on targeted social media campaigns and virtual consultations, companies are catering to the growing demand for convenience and privacy, fostering consumer loyalty through direct-to-consumer subscription models. This digital evolution not only reduces reliance on traditional pharmacy channels but also allows manufacturers to leverage analytics for swift adaptation to changing consumer preferences, positioning them favorably in the competitive landscape.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Short Acting Contraceptives Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Oral Contraceptive Pills
• Injectable Contraceptives
• Vaginal Rings
• Transdermal Patches
• Other Short-Acting Contraceptives

Global Short Acting Contraceptives Market Size by Hormone Type & CAGR (2026-2033)

• Market Overview
• Combined Hormonal Contraceptives
• Progestin-Only Contraceptives

Global Short Acting Contraceptives Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Family Planning Clinics

Global Short Acting Contraceptives Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Homecare

Global Short Acting Contraceptives Market Size & CAGR (2026-2033)

• North America (Product Type, Hormone Type, Distribution Channel, End User)
  • US
  • Canada
• Europe (Product Type, Hormone Type, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Hormone Type, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Hormone Type, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Hormone Type, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exeltis Healthcare S.L.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratorios Leon Farma, S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HRA Pharma SAS
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gedeon Richter Plc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Dahua Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Afaxys Pharma, LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Perrigo Company plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations